US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Launch of småå in focus for Emplicure

As Emplicure reports the first quarter of 2023, it is fully focused on the launch of the new tobacco-free nicotine product småå. The company has also carried out a directed share issue of 25 MSEK, gaining a new majority shareholder. BioStock contacted CEO Håkan Engqvist to find out more about his view on the latest developments and the near future.Read the full article at biostock.se : https://www.biostock.se/2023/05/launch-of-smaa-in-focus-for-emplicure/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock: Development in focus for Emplicure after results in PK study

Emplicure has focused on development work during the fourth quarter of 2022. During the period, the company completed an exploratory PK study with Empli03, which showed a steady profile and extended release. After the results were presented, the company announced that the development of the candidate is progressing. Emplicure also initiated a collaboration with OnDosis in the field of pain management. BioStock contacted CEO Håkan Engqvist to find out more about the last quarter.Read the full article about Emplicure at biostock.se: https://www.biostock.se/en/2023/03/development-in-focus-

BioStock: Emplicure continues development work with Empli03

After receiving results from the PKstudy with Empli03, Emplicure is now moving forward with the formulation development of the candidate. The company also recently initiated a collaboration with OnDosis to develop better pain treatments. BioStock  talked to CEO Håkan Engqvist.Read the full article about Emplicure at biostock.se: https://www.biostock.se/en/2023/03/emplicure-continues-development-work-with-empli03/ This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se  

BioStock: PK study in focus during Emplicure’s third quarter

During Emplicure’s third quarter, the focus has been on the pharmacokinetic study with the company’s main project Empli03, which is aimed at patients with chronic pain. A new CEO was also appointed during the quarter and a holding company structure was implemented. BioStock talked to the company’s newly appointed CEO Håkan Engqvist about the past quarter.Read the full article about Emplicure at biostock.se  https://www.biostock.se/en/2022/11/pk-study-in-focus-during-emplicures-third-quarter This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.

BioStock: Emplicure's Chairman of the Board comments on the change of CEO

Emplicure enters autumn with a new CEO and an approved application for a clinical pharmacokinetic study. BioStock talked to Chairman of the Board Gisela Sitbon about the company's eventful autumn and the reasoning behind the change of CEO.Read the full article about Emplicure at biostock.se:  https://www.biostock.se/en/2022/10/emplicures-chairman-of-the-board-comments-on-the-change-of-ceo  This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en

BioStock: Emplicure’s PK study with Empli03 approved

Uppsala-based Emplicure kicks off the autumn term by advancing their main project Empli03. On Tuesday last week, British authorities approved the company’s application to conduct a clinical pharmacokinetic study with the candidate. BioStock asked Emplicure’s CEO Torbjörn W. Larsson what the announcement means for the company and what the next step in the project is.Read the article at biostock.se: https://www.biostock.se/en/2022/09/emplicures-pk-study-with-empli03-approved/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Amplicon's nicotine pouches premiered at global nicotine event

Emplicure's subsidiary Amplicon has achieved one of the most significant milestones in its history, premiering two dry white nicotine pouches at the Global Forum on Nicotine in Warsaw. In connection with this, the company also applied for trademark registration in the EU for its leading product. BioStock contacted Amplicon's Chairman of the Board Tomas Hammargren to find out more.Read the full article about Amplicon on biostock.com: https://www.biostock.se/en/2022/06/amplicons-nicotine-pouches-premiered-at-global-nicotine-event/ This is a press release from BioStock – Connecting

BioStock: Emplicure’s co-founder on the company’s next step

Since it was founded in 2014, Emplicure has transformed from being a company with potential and ambitions of going public to today having one drug candidate heading into clinical studies and a consumer product ready to premiere in June. A person who has been involved throughout the company’s journey is co-founder Thomas Lundqvist, who resigned as chairman of the board in April. BioStock spoke to Lundqvist about his new role and how he sees the company’s future.Read the full article at biostock.se : https://www.biostock.se/en/2022/05/emplicures-medgrundare-om-

BioStock: Emplicure steams towards key milestones in Amp01 and Empli03

Emplicure’s report for the first quarter of 2022 puts the emphasis on the preparations for the pharmacokinetic study with the main project Empli03. The formulation has been finalised; documentation, methods, and specifications have been transferred to the company’s research partner (CRO/CDMO) in the UK and the active ingredient has been secured. At the same time, the company are advancing the nicotine products within the Amp01 project. BioStock spoke to CEO Torbjörn W. Larsson for a comment on the first quarter.Read the full interview at biostock.se: https://www.biostock.se/en/2022/05/

BioStock: Emplicure building strong patent portfolio

In life science, robust and sustainable intellectual property protection is crucial for optimising the value of a company’s development project. This fact has motivated Uppsala-based Emplicure to work actively to strengthen the patent protection for its products. Since December, the company has announced four patent advancements in strategically important markets. BioStock contacted Emplicure’s co-founder Thomas Lundqvist, who has extensive experience in patent protection, to find out more.Read the full interview at biostock.se: https://www.biostock.se/en/2022/04/emplicure-building-

BioStock: Emplicure’s CEO on the strength of their business model

With its bioceramic platforms, Emplicure develops products at the interface between pharmacy and materials science, enabling high-precision drug delivery.  But not only that, the technology can also be applied to consumer products and the company already has several lines of business. BioStock contacted CEO Torbjörn W. Larsson to find out more about the synergies that the platforms bring with them and what this means for the company’s business strategy.Read the full interview with Emplicure's CEO Torbjörn W. Larsson at biostock.se: https://www.biostock.se/en/2022/03/emplicures-ceo-on-the-

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe